- PolyPeptide has expanded its credit facility to €200 million, adding ING Bank to its lending syndicate.
- The financing supports the company’s strategy to double its 2023 revenue by 2028 and fund capacity expansion projects.
PolyPeptide has announced the expansion of its existing credit facility to €200 million, strengthening its financial position as it advances its long-term growth strategy. The company stated that UBS will continue to act as coordinator and agent, with ING Bank joining the lending syndicate alongside Danske Bank and Zürcher Kantonalbank.
The expanded facility is intended to provide greater financial flexibility as the company pursues its objective of doubling its 2023 revenue by 2028. The strategy is supported by anticipated improvements in profitability and cash flow, as well as continued customer funding for major capacity expansion projects.
PolyPeptide operates as a CDMO focused on peptide-based active pharmaceutical ingredients, providing contract manufacturing services to pharmaceutical partners. The additional financing is expected to support ongoing investments in infrastructure and production capabilities.
“The expansion of our credit facility and the addition of ING Bank to our lending syndicate reinforce the confidence our banking partners have in PolyPeptide’s strategy and long-term growth potential.”
Juan Jose Gonzalez, Chief Executive Officer of PolyPeptide
The company indicated that the strengthened financing structure positions it to continue its growth trajectory while maintaining a stable financial foundation to support future development and contract manufacturing activities.
